Business
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":" Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual Congress 2020\n Expects screening and enrollment in RESTORE-1 trial of VY-AADC (NBIb-1817) to resume during 2H 2020 Intends to submit Investigational New Drug (IND) application of VY-HTT01 for Huntington’s disease during 2H 2020 CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its second quarter 2020 financial results, program progress and corporate updates. “We anticipate making important progress across our lead programs in the coming months, including presenting long-term clinical results from our Parkinson’s disease gene therapy program, resuming patient screening and enrollment in our RESTORE-1 trial for Parkinson’s patients, and moving our wholly-owned gene therapy for Huntington’s disease toward the clinic with an IND filing,” said Andre Turenne, President and CEO of Voyager. “We’re also excited to continue momentum on our next generation capsids, which we believe have the potential to substantially enhance and expand the therapeutic potential of AAV gene therapy to treat severe neurological diseases.” Corporate Highlights and Program Outlook VY-AADC (NBIb-1817) in Parkinson’s Disease Voyager and Neurocrine Biosciences plan to present the final three-year data on all three cohorts of the PD-1101 Phase 1b trial, as well as two-year data from the PD-1102 Phase 1 trial, at the MDS Virtual Congress 2020 being held in September. In total, these data will represent more than 60 years of patient experience following VY-AADC treatment and will include a range of patient-reported, physician-assessed and objective endpoints. Voyager and Neurocrine Biosciences expect patient screening and enrollment to resume at clinical sites in the RESTORE-1 Phase 2 clinical trial during the second half of 2020. Trial sites had temporarily suspended patient screening and enrollment activity in response to the COVID-19 pandemic and the implementation of protocol amendments.Voyager and Neurocrine Biosciences plan to initiate the RESTORE-2 Phase 3 global registrational clinical study of VY-AADC (NBIb-1817) in Parkinson’s disease during the first half of 2021.Voyager and collaborators recently published a review of the evolution of novel tech...